Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
operating margin TTM
revenue TTM
revenue per share TTM
valuation ratios | |
|---|---|
| pe ratio | 278.09 |
| peg ratio | 2.20 |
| price to book ratio | 61.35 |
| price to sales ratio | 0.82 |
| enterprise value multiple | 6.25 |
| price fair value | 61.35 |
profitability ratios | |
|---|---|
| gross profit margin | 97.89% |
| operating profit margin | 14.76% |
| pretax profit margin | 35.44% |
| net profit margin | 36.62% |
| return on assets | 18.67% |
| return on equity | 30.88% |
| return on capital employed | 7.93% |
liquidity ratio | |
|---|---|
| current ratio | 11.01 |
| quick ratio | 11.01 |
| cash ratio | 10.98 |
efficiency ratio | |
|---|---|
| days of inventory outstanding | 0.00 |
| operating cycle | 0.57 |
| days of payables outstanding | 821.56 |
| cash conversion cycle | -820.99 |
| receivables turnover | 636.90 |
| payables turnover | 0.44 |
| inventory turnover | 0.00 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.01 |
| debt equity ratio | 0.01 |
| long term debt to capitalization | 0.00 |
| total debt to capitalization | 0.01 |
| interest coverage | 0.00 |
| cash flow to debt ratio | -45.18 |
cash flow ratios | |
|---|---|
| free cash flow per share | -0.03 |
| cash per share | 0.07 |
| operating cash flow per share | -0.03 |
| free cash flow operating cash flow ratio | 1.00 |
| cash flow coverage ratios | -45.18 |
| short term coverage ratios | -50.88 |
| capital expenditure coverage ratio | 0.00 |
Frequently Asked Questions
When was the last time Neuphoria Therapeutics Inc. (NASDAQ:NEUP) reported earnings?
Neuphoria Therapeutics Inc. (NEUP) published its most recent earnings results on N/A.
What is Neuphoria Therapeutics Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Neuphoria Therapeutics Inc. (NASDAQ:NEUP)'s trailing twelve months ROE is 30.88%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Neuphoria Therapeutics Inc. (NEUP) currently has a ROA of 18.67%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did NEUP's net profit margin stand at?
NEUP reported a profit margin of 36.62% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is NEUP's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 11.01 in the most recent quarter. The quick ratio stood at 11.01, with a Debt/Eq ratio of 0.01.